Therapeutic Advances in Heart failure

Costs of providing a particular medical service can be measured, but it is more difficult to assess whether the service provides good value for the money spent. Extensive cost-effectiveness studies have been conducted on many important cardiovascular therapies:

  • β-blockers and diuretics for multiple CVD outcomes, mortality, and prevention of recurrent myocardial infarction (MI);
  • Statins for both primary and secondary prevention of CVD;
  • Enalapril for prevention and treatment of congestive heart failure;
  • Tissue plasminogen activator treatment of acute MI;
  • Coronary artery bypass graft for left main, single-, and 2-vessel coronary artery disease, or severe angina;
  • Physician counselling for smoking; and
  • Radiofrequency ablation therapy for Wolff-Parkinson-White syndrome.
  • Anticoagulation Therapy and Thrombosis Prevention
  • Aortic Stenosis and TAVR

 

    Related Conference of Therapeutic Advances in Heart failure

    May 30-31, 2024

    6th Euro Cardiology Congress

    Vienna, Austria
    May 30-31, 2024

    39th World Congress on Heart Diseases

    Vienna, Austria
    June 20-21, 2024

    5th European Summit on Cardiology Research

    Dublin, Ireland
    July 16-17, 2024

    13th World Heart Congress

    Paris, France
    August 01-02, 2024

    38th World Congress on Heart Diseases

    Montreal, Canada
    September 16-17, 2024

    3rd Global Summit on Cardiology and Cardiac Surgery

    Paris, France
    October 24-25, 2024

    11th International Conference on Interventional Cardiology

    Zurich, Switzerland
    October 30-31, 2024

    7th Global Cardiovascular Research and Clinical Cardiology

    Vancouver, Canada

    Therapeutic Advances in Heart failure Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in